The launch of a new subtype-driven online resource for professionals treating and researching lymphoma and chronic lymphocytic leukemia (CLL) blood cancers, was announced at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, Calif., Dec. 3-6.
The conference presentation about Lymphoma Hub was made by Gilles Salles, head of the Haematology Department of the South Lyon Hospital Complex, a teacher at the Claude Bernard University of Lyon, France, and chairman of the project.
Under the guidance of world leaders in the lymphoma and CLL fields, the Lymphoma Hub is an authoritative source of information on the latest developments in treatment options, case studies, and expert opinions and recommendations organized by subtypes and accessible via a variety of digital channels. Lymphoma Hub supports the hematology and oncology communities in making better-informed treatment decisions and helping ensure that patients are provided with access to the latest and most effective therapies available.
“Our mission is to provide up-to-date, practical, clinical advice to community hematologists and oncologists seeking treatment options for lymphoma and CLL, to improve the lives of patients,” Lymphoma Hub’s mission statement reads.
With this resource accessible anywhere there’s a live Internet connection, users will be able to quickly build patient profiles based on individual diagnoses in order to identify the optimum treatment options available, whether they are licensed therapies or undergoing actively recruiting clinical trials.
The initial challenge that lymphoma and CLL presents for hematologists, oncologists and researchers working in blood cancer fields is accurate diagnosis. With more than 70 lymphoma subtypes in various settings (i.e., newly diagnosed or relapsed/refractory), identifying and making appropriate treatment decisions that will provide patients with the best possible outcomes is paramount.
Noting that recent increases in approvals, line extensions and clinical studies have made determining the ideal treatment for each individual patient even more challenging, the Lymphoma Hub developers perceived a need for a unified, authoritative, up-to-date, and practical resource to help members of the hematology and oncology communities improve their understanding of the latest lymphoma and CLL treatment and management options.
As Lymphoma Hub chairman, Salles has projected it will become the reference resource of first resort for professionals treating these disorders.
A short video explaining the benefits of the launched subtype driven Lymphoma Hub can be accessed at: https://youtu.be/QY_p5Y6ziJ4